HK1070287A1 - Hepatitis c virus inhibitors - Google Patents

Hepatitis c virus inhibitors

Info

Publication number
HK1070287A1
HK1070287A1 HK05103045.4A HK05103045A HK1070287A1 HK 1070287 A1 HK1070287 A1 HK 1070287A1 HK 05103045 A HK05103045 A HK 05103045A HK 1070287 A1 HK1070287 A1 HK 1070287A1
Authority
HK
Hong Kong
Prior art keywords
hepatitis
virus inhibitors
virus
inhibitors
Prior art date
Application number
HK05103045.4A
Other languages
English (en)
Inventor
Xiangdong Alan Wang
Li-Quang Sun
Sing-Yuen Sit
Ny Sin
Paul Michael Scola
Piyasena Hewawasam
Andrew Charles Good
Yan Chen
Jeffrey Allen Campbell
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29584353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1070287(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HK1070287A1 publication Critical patent/HK1070287A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK05103045.4A 2002-05-20 2005-04-11 Hepatitis c virus inhibitors HK1070287A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38205502P 2002-05-20 2002-05-20
PCT/US2003/015755 WO2003099274A1 (fr) 2002-05-20 2003-05-20 Inhibiteurs du virus de l'hepatite c

Publications (1)

Publication Number Publication Date
HK1070287A1 true HK1070287A1 (en) 2005-06-17

Family

ID=29584353

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05103045.4A HK1070287A1 (en) 2002-05-20 2005-04-11 Hepatitis c virus inhibitors

Country Status (34)

Country Link
US (9) US6995174B2 (fr)
EP (2) EP2340830A3 (fr)
JP (1) JP4312710B2 (fr)
KR (2) KR20100093140A (fr)
CN (3) CN1974596B (fr)
AR (3) AR040080A1 (fr)
AT (1) ATE506104T1 (fr)
AU (1) AU2003241510B2 (fr)
BR (1) BR0311132A (fr)
CA (1) CA2486308C (fr)
CO (1) CO5640083A2 (fr)
CY (1) CY1112108T1 (fr)
DE (1) DE60336807D1 (fr)
DK (1) DK1505963T3 (fr)
ES (1) ES2363131T3 (fr)
GE (1) GEP20063938B (fr)
HK (1) HK1070287A1 (fr)
HR (1) HRP20041085B1 (fr)
IL (1) IL164987A (fr)
IS (1) IS7530A (fr)
MX (1) MXPA04011440A (fr)
MY (1) MY140680A (fr)
NO (1) NO332427B1 (fr)
NZ (1) NZ536539A (fr)
PE (1) PE20040517A1 (fr)
PL (1) PL226561B1 (fr)
PT (1) PT1505963E (fr)
RS (1) RS52407B (fr)
RU (3) RU2298001C2 (fr)
SI (1) SI1505963T1 (fr)
TW (1) TWI306452B (fr)
UA (1) UA80973C2 (fr)
WO (1) WO2003099274A1 (fr)
ZA (1) ZA200409162B (fr)

Families Citing this family (279)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20060199773A1 (en) * 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
EP1601685A1 (fr) * 2003-03-05 2005-12-07 Boehringer Ingelheim International GmbH Composes d'inhibition de l'hepatite c
DE602004029866D1 (de) * 2003-03-05 2010-12-16 Boehringer Ingelheim Pharma Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
ATE422895T1 (de) * 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
PT1654261E (pt) 2003-05-21 2008-01-18 Boehringer Ingelheim Int Compostos inibidores da hepatite c
US7273851B2 (en) 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) * 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2549851C (fr) 2004-01-21 2012-09-11 Boehringer Ingelheim International Gmbh Peptides macrocycliques actifs contre le virus de l'hepatite c
AR048401A1 (es) 2004-01-30 2006-04-26 Medivir Ab Inhibidores de la serina-proteasa ns3 del vhc
SE0400199D0 (sv) * 2004-01-30 2004-01-30 Medivir Ab HCV Protease inhbitors
US7582770B2 (en) 2004-02-20 2009-09-01 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
RU2006136084A (ru) * 2004-03-15 2008-04-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Способ получения микроциклических соединений
BRPI0509467A (pt) * 2004-03-30 2007-09-11 Intermune Inc compostos macrocìclicos como inibidores de replicação viral
JP5156374B2 (ja) 2004-05-25 2013-03-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 非環式ｈｃｖプロテアーゼインヒビターの調製方法
CA2556669C (fr) * 2004-06-28 2012-05-01 Boehringer Ingelheim International Gmbh Analogues peptidiques d'inhibiteurs de l'hepatite c
CN101022803B (zh) 2004-07-09 2011-11-23 药物合成技术公司 治疗化合物和治疗
AR050174A1 (es) 2004-07-16 2006-10-04 Gilead Sciences Inc Derivados de fosfonatos con actividad antiviral. composiciones farmaceuticas
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
EP1771454B1 (fr) * 2004-07-20 2011-06-15 Boehringer Ingelheim International GmbH Analogues peptidiques inhibiteurs de l'hepatite c
US7550559B2 (en) * 2004-08-27 2009-06-23 Schering Corporation Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
ES2442678T3 (es) 2004-08-28 2014-02-12 Astrazeneca Ab Derivados de pirimidín sulfonamidas como moduladores del receptor de quimioquina
US7846915B2 (en) 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
US7879797B2 (en) 2005-05-02 2011-02-01 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US7592336B2 (en) * 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
EP1910378B1 (fr) * 2005-07-20 2012-06-20 Boehringer Ingelheim International GmbH Analogues de peptides inhibiteurs de l'hepatite c
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
JP5249028B2 (ja) 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
TWI375670B (en) 2005-07-29 2012-11-01 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
ATE496042T1 (de) 2005-07-29 2011-02-15 Tibotec Pharm Ltd Makrocyclische inhibitoren des hepatitis-c-virus
AU2006275514B2 (en) 2005-07-29 2012-04-05 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
KR20080036598A (ko) 2005-08-01 2008-04-28 머크 앤드 캄파니 인코포레이티드 Ｈｃｖ ｎｓ３ 프로테아제 억제제로서의 마크로사이클릭펩티드
EP1915378A4 (fr) 2005-08-12 2009-07-22 Boehringer Ingelheim Int Inhibiteurs de polymerase virale
DE602006019323D1 (de) 2005-10-11 2011-02-10 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
ES2543840T3 (es) * 2006-04-11 2015-08-24 Novartis Ag Inhibidores espirocíclicos del VHC/VIH y sus usos
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
US7728148B2 (en) * 2006-06-06 2010-06-01 Enanta Pharmaceuticals, Inc. Acyclic oximyl hepatitis C protease inhibitors
US20080187516A1 (en) * 2006-06-06 2008-08-07 Ying Sun Acyclic oximyl hepatitis c protease inhibitors
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
UY30437A1 (es) * 2006-06-26 2008-01-31 Enanta Pharm Inc Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
WO2008008776A2 (fr) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
EA017448B1 (ru) 2006-07-13 2012-12-28 Ачиллион Фармасьютикалз, Инк. 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации
US7635683B2 (en) * 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US20090035267A1 (en) * 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
US20090098085A1 (en) * 2006-08-11 2009-04-16 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
EP1886685A1 (fr) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X
US7687459B2 (en) * 2006-08-11 2010-03-30 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis C virus protease inhibitors
US20080038225A1 (en) * 2006-08-11 2008-02-14 Ying Sun Triazolyl acyclic hepatitis c serine protease inhibitors
RU2009109355A (ru) 2006-08-17 2010-09-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Ингибиторы вырусной полимеразы
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
WO2008051514A2 (fr) 2006-10-24 2008-05-02 Merck & Co., Inc. Inhibiteurs de la protéase ns3 du hcv
AU2007309546A1 (en) 2006-10-24 2008-05-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HCV NS3 protease inhibitors
CN101568346B (zh) 2006-10-27 2015-11-25 默沙东公司 Hcv ns3蛋白酶抑制剂
CA2667031C (fr) * 2006-10-27 2013-01-22 Merck & Co., Inc. Inhibiteurs de protease ns3 du vhc
US20080107623A1 (en) * 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US20080107625A1 (en) * 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US20080108632A1 (en) * 2006-11-02 2008-05-08 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008070358A2 (fr) * 2006-11-16 2008-06-12 Phenomix Corporation Inhibiteurs de la sérine protéase de l'hépatite c et utilisations de ceux-ci
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) * 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9828597B2 (en) 2006-11-22 2017-11-28 Toyota Motor Engineering & Manufacturing North America, Inc. Biofunctional materials
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2007335962B2 (en) 2006-12-20 2012-09-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Antiviral indoles
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
US20080161254A1 (en) * 2007-01-03 2008-07-03 Virobay, Inc. Hcv inhibitors
WO2008095058A1 (fr) * 2007-02-01 2008-08-07 Taigen Biotechnology Co. Ltd. Inhibiteurs de la protéase du virus de l'hépatite c
CN101641339B (zh) 2007-02-01 2013-07-17 雷斯韦洛吉克斯公司 用于预防和治疗心血管疾病的化合物
EP2118091B1 (fr) 2007-02-08 2015-04-15 Janssen Sciences Ireland UC Inhibiteurs macrocycliques du virus de l'hépatite c (vhc) substitués par pyrimidine
EP2495249A1 (fr) * 2007-02-26 2012-09-05 Achillion Pharmaceuticals, Inc. Peptides à amine tertiaire substituée utiles en tant qu'inhibiteurs de la réplication du VHC
US20080317712A1 (en) * 2007-04-26 2008-12-25 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl tripeptide hepatitis c serine protease inhibitors
US20080267917A1 (en) * 2007-04-26 2008-10-30 Deqiang Niu N-functionalized amides as hepatitis c serine protease inhibitors
US8377872B2 (en) 2007-04-26 2013-02-19 Enanta Pharmaceuticals, Inc. Cyclic P3 tripeptide hepatitis C serine protease inhibitors
US7910587B2 (en) * 2007-04-26 2011-03-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl dipeptide hepatitis C virus inhibitors
US20080292587A1 (en) * 2007-04-26 2008-11-27 Ying Sun Oximyl dipeptide hepatitis c protease inhibitors
EP2177523A1 (fr) * 2007-05-03 2010-04-21 Intermune, Inc. Nouveaux inhibiteurs macrocycliques de réplication du virus de l'hépatite C
JP2010526834A (ja) * 2007-05-10 2010-08-05 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規ペプチド阻害剤
US20090005387A1 (en) * 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
AR067180A1 (es) * 2007-06-29 2009-09-30 Gilead Sciences Inc Compuestos antivirales
US8513186B2 (en) 2007-06-29 2013-08-20 Gilead Sciences, Inc. Antiviral compounds
EP2162431B1 (fr) 2007-06-29 2017-06-07 Gilead Sciences, Inc. Composés antiviraux
EP2178885A1 (fr) 2007-07-17 2010-04-28 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Dérivés macrocycliques d'indole pour le traitement des infections d'hépatite c
WO2009010804A1 (fr) 2007-07-19 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Composes macrocycliques servant d'agents antiviraux
US8242140B2 (en) 2007-08-03 2012-08-14 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2700383A1 (fr) 2007-09-24 2009-04-02 Achillion Pharmaceuticals, Inc. Peptides contenant de l'uree en tant qu'inhibiteurs de la replication virale
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
WO2009055335A2 (fr) * 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Inhibiteurs des protéases du vhc
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
CL2008003384A1 (es) * 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
WO2009064955A1 (fr) 2007-11-14 2009-05-22 Enanta Pharmaceuticals, Inc. Inhibiteurs macrocycliques à radical tétrazolyle de la sérine protéase du virus de l'hépatite c
WO2009070692A1 (fr) * 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. Inhibiteurs de sérine protéase de l'hépatite c macrocycliques, dérivés de la proline, substitués en c5
WO2009070689A1 (fr) * 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. Dérivés de proline bicycliques substitués en c5 en tant qu'inhibiteurs de la protéase ns3 du virus de l'hépatite c
WO2009076173A2 (fr) 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Composés à base de tripeptides fluorés inhibant la sérine protéase du vhc
US8361958B2 (en) * 2007-12-05 2013-01-29 Enanta Pharmaceuticals, Inc. Oximyl HCV serine protease inhibitors
CN101932242A (zh) 2007-12-05 2010-12-29 益安药业 喹喔啉基衍生物
WO2009079353A1 (fr) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Inhibiteurs macrocycliques contenant du triazole des protéases à sérine du vhc
MX2010006518A (es) 2007-12-14 2010-08-10 Enanta Pharm Inc Inhibidores de serina proteasa de hepatitis c de oximil macrociclica.
US8476257B2 (en) 2007-12-19 2013-07-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2709535A1 (fr) * 2007-12-21 2009-07-02 Avila Therapeutics, Inc. Inhibiteurs de hcv protease et leurs utilisations
AU2013231052B2 (en) * 2007-12-21 2015-09-10 Bristol-Myers Squibb Holdings Ireland Unlimited Company Crystalline forms of n-(tert-butoxycarbonyl)-3-methyl-l-valyl-(4r)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-n-((1r,2s)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-l-prolinamide
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
WO2009082701A1 (fr) 2007-12-21 2009-07-02 Avila Therapeutics, Inc. Inhibiteurs de hcv protéase et leurs utilisations
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8101567B2 (en) * 2008-01-24 2012-01-24 Enanta Pharmaceuticals, Inc. Heteroaryl-containing tripeptide HCV serine protease inhibitors
CN102036966A (zh) * 2008-01-24 2011-04-27 益安药业 作为hcv丝氨酸蛋白酶抑制剂的二氟化三肽
EP2250174B1 (fr) 2008-02-04 2013-08-28 IDENIX Pharmaceuticals, Inc. Inhibiteurs de sérine protéase macrocycliques
CN102015652A (zh) 2008-03-20 2011-04-13 益安药业 作为丙型肝炎病毒抑制剂的氟化大环化合物
SG175692A1 (en) * 2008-04-15 2011-11-28 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2720850A1 (fr) 2008-04-28 2009-11-05 Merck Sharp & Dohme Corp. Inhibiteurs de la protease hcv ns3
US20090285773A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20090285774A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN101580535B (zh) * 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5529120B2 (ja) 2008-05-29 2014-06-25 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
KR101629356B1 (ko) 2008-06-26 2016-06-13 리스버로직스 코퍼레이션 퀴나졸리논 유도체의 제조방법
TW201004632A (en) 2008-07-02 2010-02-01 Idenix Pharmaceuticals Inc Compounds and pharmaceutical compositions for the treatment of viral infections
PL2310095T3 (pl) 2008-07-22 2013-03-29 Msd Italia Srl Makrocykliczne związki chinoksaliny jako inhibitory proteazy NS3 HCV
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8748650B2 (en) 2008-08-29 2014-06-10 Jsr Corporation Method for production of N-carboxy amino acid anhydride and amino acid carbamate compound
US8207341B2 (en) * 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100080770A1 (en) * 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8383094B2 (en) * 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100272674A1 (en) * 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
SI2364309T1 (sl) * 2008-12-10 2015-03-31 Achillion Pharmaceuticals, Inc. Novi 4-amino-4-oksobutanoil peptidi kot inhibitorji virusne replikacije
CA2746265A1 (fr) * 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. Analogues cycliques de peptides a-amino-4-oxobutanoyl, inhibiteurs de la replication virale
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2379579A1 (fr) 2008-12-19 2011-10-26 Gilead Sciences, Inc. Inhibiteurs de la protéase ns3 du vhc
JP2012513397A (ja) 2008-12-22 2012-06-14 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
SG172848A1 (en) 2009-01-07 2011-08-29 Scynexis Inc Cyclosporine derivative for use in the treatment of hcv and hiv infection
AU2010204106B2 (en) 2009-01-08 2014-05-08 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
CA2751892A1 (fr) 2009-01-15 2010-07-22 Rutgers, The State University Of New Jersey Benzo[c]phenanthridines comme agents antimicrobiens
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
MX2021012876A (es) 2009-03-18 2022-06-23 Resverlogix Corp Nuevos agentes anti-inflamatorios.
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
ES2821018T3 (es) 2009-04-22 2021-04-23 Resverlogix Corp Nuevos agentes antiinflamatorios
WO2010127307A1 (fr) * 2009-04-30 2010-11-04 Rutgers, The State University Of New Jersey Agents antimicrobiens
EP2429568B1 (fr) 2009-05-13 2016-08-17 Enanta Pharmaceuticals, Inc. Composés macrocycliques comme inhibiteurs du virus de l'hépatite c
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
WO2011014487A1 (fr) 2009-07-30 2011-02-03 Merck Sharp & Dohme Corp. Inhibiteurs de protéase ns3 du virus de l'hépatite c
AR077712A1 (es) 2009-08-05 2011-09-14 Idenix Pharmaceuticals Inc Inhibidores de serina proteasa macrociclica
US8389560B2 (en) 2009-09-15 2013-03-05 Taigen Biotechnology Co., Ltd. HCV protease inhibitors
CA2775697A1 (fr) * 2009-09-28 2011-03-31 Intermune, Inc. Inhibiteurs peptiques cycliques de la replication du virus de l'hepatite c
US8415374B2 (en) * 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
WO2011049908A2 (fr) * 2009-10-19 2011-04-28 Enanta Pharmaceuticals, Inc. Composés bismacrocycliques à titre d'inhibiteurs du virus de l'hépatite c
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011063076A1 (fr) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Méthodes de traitement du virus de l'hépatite c avec des composés d'oxo-acétamide
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MY159958A (en) * 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110178107A1 (en) * 2010-01-20 2011-07-21 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
EP2552203B1 (fr) 2010-04-01 2017-03-22 Idenix Pharmaceuticals LLC. Composés et compositions pharmaceutiques pour le traitement d'infections virales
CA2810162A1 (fr) 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Agents antimicrobiens
US9121016B2 (en) 2011-09-09 2015-09-01 Toyota Motor Engineering & Manufacturing North America, Inc. Coatings containing polymer modified enzyme for stable self-cleaning of organic stains
US11015149B2 (en) 2010-06-21 2021-05-25 Toyota Motor Corporation Methods of facilitating removal of a fingerprint
US10988714B2 (en) 2010-06-21 2021-04-27 Regents Of The University Of Minnesota Methods of facilitating removal of a fingerprint from a substrate or a coating
US8796009B2 (en) 2010-06-21 2014-08-05 Toyota Motor Engineering & Manufacturing North America, Inc. Clearcoat containing thermolysin-like protease from Bacillus stearothermophilus for cleaning of insect body stains
US9388370B2 (en) * 2010-06-21 2016-07-12 Toyota Motor Engineering & Manufacturing North America, Inc. Thermolysin-like protease for cleaning insect body stains
WO2011163610A2 (fr) 2010-06-25 2011-12-29 Rutgers, The State University Of New Jersey Agents antimicrobiens
US20120196794A1 (en) * 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
PE20140015A1 (es) 2010-09-21 2014-02-16 Enanta Pharm Inc Inhibidores de las proteasas de serina del vhc derivados de prolinas macrociclicas
BR112013008148A2 (pt) 2010-09-24 2016-08-09 Bristol Myers Squibb Co "inibidores do vírus da hepatite c".
CA2815855C (fr) 2010-11-01 2016-02-02 Rfs Pharma, Llc Nouveaux inhibiteurs specifiques de la protease ns3 du vhc
EP2651884A2 (fr) * 2010-12-14 2013-10-23 Merck Sharp & Dohme Corp. Procédé et intermédiaires pour la préparation de macrolactames
WO2012087833A1 (fr) 2010-12-22 2012-06-28 Abbott Laboratories Inhibiteurs de l'hépatite c et leurs utilisations
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
AU2011352145A1 (en) 2010-12-30 2013-07-18 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
WO2012109398A1 (fr) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de sérine protéase, compositions pharmaceutiques les contenant et leur utilisation pour le traitement des infections par le vhc
WO2012107589A1 (fr) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement et la prévention des infections à vhc
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP2691409B1 (fr) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Composés et compositions pharmaceutiques pour le traitement d'infections virales
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2012166459A1 (fr) * 2011-05-27 2012-12-06 Bristol-Myers Squibb Company Tripeptides incorporant du deutérium en tant qu'inhibiteurs du virus de l'hépatite c
MX349079B (es) * 2011-05-27 2017-07-07 Achillion Pharmaceuticals Inc Alifanos, ciclofanos, heterafanos, heterofanos, hetero-heterafanos y metalocenos sustituidos utiles para tratar infecciones por el vhc.
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102911254A (zh) * 2011-08-02 2013-02-06 上海唐润医药科技有限公司 Hcv蛋白酶抑制剂
US8951985B2 (en) 2011-09-12 2015-02-10 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2755983B1 (fr) 2011-09-12 2017-03-15 Idenix Pharmaceuticals LLC. Composés de carbonyloxyméthylphosphoramidate substitué et compositions pharmaceutiques servant à traiter les infections virales
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
GB2515941A (en) 2011-10-21 2015-01-07 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EA201490836A1 (ru) 2011-10-21 2014-11-28 Эббви Инк. Комбинационное лечение (например, с abt-072 или abt-333) с помощью daa для применения при лечении hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
PT2773354T (pt) 2011-11-01 2019-07-17 Resverlogix Corp Formulações orais de libertação imediata para quinazolinonas substituídas
EP2780026B1 (fr) 2011-11-15 2019-10-23 Merck Sharp & Dohme Corp. Inhibiteurs de la protéase ns3 du vhc
EP2785184B1 (fr) 2011-11-30 2020-06-10 Emory University Compositions contenant des inhibiteurs de jak et des médicaments haart destinées à la prévention ou au traitement du vih
MX355102B (es) 2012-01-11 2018-04-05 Abbvie Ireland Unlimited Co Procesos para hacer los inhibidores de la proteasa del hcv.
US9040479B2 (en) 2012-01-12 2015-05-26 Cocrystal Pharma, Inc. HCV NS3 protease inhibitors
WO2013106756A2 (fr) 2012-01-13 2013-07-18 Rutgers, The State University Of New Jersey Agents antimicrobiens
WO2013133927A1 (fr) 2012-02-13 2013-09-12 Idenix Pharmaceuticals, Inc. Compositions pharmaceutiques de 2'-c-méthyl-guanosine, 5'-[2-[(3-hydroxy-2,2-diméthyl-1-oxopropyl)thio]éthyl n-(phénylméthyl)phosphoramidate]
AU2013229229B2 (en) 2012-03-07 2017-10-19 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
US9475783B2 (en) 2012-03-21 2016-10-25 Rutgers, The State University Of New Jersey Antimicrobial agents
US20130302414A1 (en) 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
JP2015516421A (ja) 2012-05-07 2015-06-11 ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｈｏｌｄｉｎｇｓ Ｉｒｅｌａｎｄ １，１−ジメチルエチル［（１ｓ）−１−｛［（２ｓ，４ｒ）−４−（７−クロロ−４メトキシイソキノリン−１−イルオキシ）−２−（｛（１ｒ，２ｓ）−１−［（シクロプロピルスルホニル）カルバモイル］−２−エテニルシクロプロピル｝カルバモイル）ピロリジン−１−イル］カルボニル｝−２，２−ジメチルプロピル］カルバメートの経口固形製剤
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
EP2852604B1 (fr) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC Promédicaments de 3',5'-phosphoramidate cyclique pour traiter une infection par le virus de l'hépatite c
AU2013266393B2 (en) 2012-05-22 2017-09-28 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
ES2773272T3 (es) * 2012-08-08 2020-07-10 Merck Patent Gmbh Derivados de (aza-)isoquinolinona
ES2674980T3 (es) 2012-10-08 2018-07-05 Idenix Pharmaceuticals Llc Análogos de 2'-cloro nucleósidos para infección por VHC
MX360452B (es) 2012-10-19 2018-11-01 Bristol Myers Squibb Co Inhibidores del virus de la hepatitis c.
EP2909223B1 (fr) 2012-10-19 2017-03-22 Idenix Pharmaceuticals LLC Composés dinucléotides contre une infection par le vhc
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (fr) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (fr) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
WO2014078436A1 (fr) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. Ester de d-alanine d'analogue de sp-nucléoside
CN103804208B (zh) * 2012-11-14 2016-06-08 重庆博腾制药科技股份有限公司 一种丙肝药物中间体的制备方法
WO2014080291A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Dérivés biaryle servant d'inhibiteurs de bromodomaines
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
EP2935304A1 (fr) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro-nucléosides pour le traitement du vhc
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014137869A1 (fr) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
EA201591722A1 (ru) 2013-03-14 2016-02-29 Ачиллион Фармасьютикалз, Инк. Новые способы получения совапревира
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2014145600A1 (fr) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Polymorphes de sel de sodium d'ach-0142684, composition les comprenant, et leur procédé de fabrication
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
KR20160005686A (ko) 2013-03-15 2016-01-15 아칠리온 파르마세우티칼스 인코포레이티드 소바프레비르 다형체들 및 이의 제조 방법
WO2014165542A1 (fr) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoronucléosides pour le traitement du vhc
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
EP3027636B1 (fr) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC Phosphoramidate de d-acides aminés pronucleotidiques dérivés de pyrimidine halogenée pour des maladies du foie
NO3044221T3 (fr) 2013-09-11 2018-07-21
US20160229866A1 (en) 2013-09-20 2016-08-11 Idenix Pharmaceuticals Inc. Hepatitis c virus inhibitors
WO2015061683A1 (fr) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. Pronucléotides thiophosphoramidates à acide aminé d et pronucléotides thiophosphoramidates à d-analine de composés de nucléoside utiles pour le traitement du vhc
EP3063165A1 (fr) 2013-11-01 2016-09-07 Idenix Pharmaceuticals LLC Pronucléotides phosphoramidates de d-alanine de composés de nucléoside 2'-méthyl 2'-fluoro guanosine dans le traitement du vhc
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
EP3074399A1 (fr) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC Analogues de nucléoside 2'-dichloro et 2'-fluoro-2'-chloro analogues pour l'infection par le vhc
WO2015095419A1 (fr) 2013-12-18 2015-06-25 Idenix Pharmaceuticals, Inc. Nucléosides 4'-or pour le traitement du vhc
EP3089757A1 (fr) 2014-01-03 2016-11-09 AbbVie Inc. Formes galéniques antivirales solides
EP3114122A1 (fr) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Formes solides d'un composé inhibiteur des virus de la famille des flaviviridae et sels de celui-ci
WO2015134561A1 (fr) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Compositions pharmaceutiques comprenant un inhibiteur de flaviviridae hétéroarylène fusionné en 5,5 et son utilisation pour le traitement ou la prévention d'une infection par les flaviviridae
WO2015134780A1 (fr) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Formes solides de promédicaments de 2'-chloro-2'-méthyl uridine pour lutter contre le vhc
WO2015161137A1 (fr) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. Nucléosides méthyle ou alcynyle substitués en position 3 pour le traitement du virus de l'hépatite c
WO2015200305A1 (fr) 2014-06-25 2015-12-30 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
AU2016333987A1 (en) 2015-10-05 2018-05-10 Ny State Psychiatric Institute Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
US10513528B2 (en) 2016-02-25 2019-12-24 Taxis Pharmaceuticals, Inc. Synthetic processes and intermediates
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
CN107641099A (zh) * 2016-07-20 2018-01-30 广东东阳光药业有限公司 取代的4‑羟基喹啉类化合物的制备方法
WO2018026877A1 (fr) 2016-08-05 2018-02-08 Calitor Sciences, Llc Méthode de préparation de composés de quinoléine-4-ol substitués
US10774093B2 (en) 2017-03-30 2020-09-15 Taxis Pharmaceuticals, Inc. Synthetic processes and synthetic intermediates
US11472778B2 (en) * 2017-06-20 2022-10-18 University Of Massachusetts Hepatitis C virus NS3/4A protease inhibitors
CN110156684A (zh) * 2019-06-28 2019-08-23 珠海市柏瑞医药科技有限公司 一种去甲乌药碱及其药用盐的合成工艺
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN113402450B (zh) * 2021-01-13 2023-11-24 上海睿腾医药科技有限公司 一种2-溴-4-氯吡啶的纯化方法
WO2023239729A1 (fr) 2022-06-08 2023-12-14 Xenon Pharmaceuticals Inc. Dérivés de pyridinamine et leur utilisation en tant que modulateurs des canaux potassiques

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US185001A (en) 1876-12-05 Improvement in measuring-faucets
JPS57123181A (en) 1981-01-23 1982-07-31 Mitsubishi Paper Mills Ltd Preparation of pyrazolo (1,5-a) pyridine derivative
EP0475255A3 (en) 1990-09-12 1993-04-14 F. Hoffmann-La Roche Ag Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5500208A (en) 1994-06-07 1996-03-19 The Procter & Gamble Company Oral compositions comprising a novel tripeptide
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
GB9517022D0 (en) 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
US5633388A (en) * 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
AU2933797A (en) 1996-05-10 1997-12-05 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
JP4080541B2 (ja) * 1996-10-18 2008-04-23 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害因子
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
PL334846A1 (en) 1997-01-23 2000-03-27 Hoffmann La Roche Sulphamidic inhibitors of metaloproteases
AU7127298A (en) 1997-04-14 1998-11-11 Emory University Serine protease inhibitors
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
ES2241157T3 (es) 1997-08-11 2005-10-16 Boehringer Ingelheim (Canada) Ltd. Peptidos inhibidores de la hepatitis c.
EP1012180B1 (fr) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Analogues de peptides inhibiteurs de l'hepatite c
IT1299134B1 (it) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
ES2281170T3 (es) 1998-03-31 2007-09-16 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas, particularmente proteasa ns3 del virus de la hepatitis c.
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6492423B1 (en) 1998-07-27 2002-12-10 Istituto Di Ricerche Di Biologia Molecolare Pangeletti Spa Diketoacid-derivatives as inhibitors of polymerases
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
CN1325309A (zh) 1998-08-21 2001-12-05 维洛药品公司 用于治疗或预防病毒感染和相关疾病的化合物、组合物和方法
AU751201B2 (en) 1998-09-04 2002-08-08 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
AU751457B2 (en) 1998-09-25 2002-08-15 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
EP1225899A2 (fr) 1999-11-04 2002-07-31 Virochem Pharma Inc. Procede de traitement ou de prevention de l'infection virale par flaviviridae faisant appel a des analogues des nucleosides
TR200103147T1 (tr) 1999-12-27 2002-06-21 Japan Tobacco Inc. Kaynaşık halkalı bileşikler ve bunların ilaç olarak kullanımı.
JP2004509066A (ja) 2000-05-10 2004-03-25 スミスクライン・ビーチャム・コーポレイション 新規抗感染症薬
EP1299498A1 (fr) 2000-06-23 2003-04-09 General Electric Company Composition silicone adhesive par pression
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
US7012066B2 (en) 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
HUP0500456A3 (en) * 2000-11-20 2012-05-02 Bristol Myers Squibb Co Hepatitis c tripeptide inhibitors, pharmaceutical compositions comprising thereof and their use
JP2004525150A (ja) 2001-03-30 2004-08-19 スミスクライン ビーチャム コーポレーション 治療用化合物としてのピラゾロピリジン類の使用
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (fr) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Peptides macrocycliques qui agissent contre le virus de l'hepatite c
CA2370396A1 (fr) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteur de l'hepatite c
US6642204B2 (en) * 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2369970A1 (fr) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteur de l'hepatite c
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20060199773A1 (en) * 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
ATE481106T1 (de) * 2002-05-20 2010-10-15 Bristol Myers Squibb Co Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
ES2315568T3 (es) * 2002-05-20 2009-04-01 Bristol-Myers Squibb Company Inhibidores del virus de la hepatitis c basados en cicloalquilo p1' sustituido.
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
EP1506172B1 (fr) * 2002-05-20 2011-03-30 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
US20040033959A1 (en) 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
KR20050065661A (ko) 2002-11-01 2005-06-29 비로파마 인코포레이티드 벤조푸란 화합물, 조성물 및 ｃ형 간염 바이러스 감염 및관련 질병의 치료 및 예방 방법
US7601709B2 (en) * 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
KR100940619B1 (ko) 2003-02-07 2010-02-05 이난타 파마슈티칼스, 인코포레이티드 마크로사이클릭 씨형 간염 세린 단백효소 억제제
EP1601685A1 (fr) 2003-03-05 2005-12-07 Boehringer Ingelheim International GmbH Composes d'inhibition de l'hepatite c
DE602004029866D1 (de) 2003-03-05 2010-12-16 Boehringer Ingelheim Pharma Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
KR20050108420A (ko) 2003-04-02 2005-11-16 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스 프로테아제 억제제를 위한 약제학적조성물
ATE422895T1 (de) 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
PT1615613E (pt) 2003-04-18 2010-02-09 Enanta Pharm Inc Inibidores da serina protease da hepatite c macrocíclicos de quinoxalinilo
PT1654261E (pt) 2003-05-21 2008-01-18 Boehringer Ingelheim Int Compostos inibidores da hepatite c
WO2004113365A2 (fr) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Inhibiteurs de la tripeptide hepatite c serine protease
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
DE602004031645D1 (de) 2003-09-22 2011-04-14 Boehringer Ingelheim Pharma Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus
CA2541634A1 (fr) 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incorporated Inhibiteurs de serine proteases, en particulier la ns3-ns4a protease du hcv
DK1680137T3 (da) 2003-10-14 2013-02-18 Hoffmann La Roche Makrocyklisk carboxylsyre- og acylsulfonamidforbindelse som inhibitor af HCV-replikation
US7132504B2 (en) * 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) * 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
EP1689770A1 (fr) 2003-11-20 2006-08-16 Schering Corporation Inhibiteurs depourvus de liaisons peptidiques de la protease ns3 du virus de l'hepatite c
CA2549851C (fr) 2004-01-21 2012-09-11 Boehringer Ingelheim International Gmbh Peptides macrocycliques actifs contre le virus de l'hepatite c
AR048401A1 (es) 2004-01-30 2006-04-26 Medivir Ab Inhibidores de la serina-proteasa ns3 del vhc
RU2006136084A (ru) 2004-03-15 2008-04-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Способ получения микроциклических соединений
BRPI0509467A (pt) 2004-03-30 2007-09-11 Intermune Inc compostos macrocìclicos como inibidores de replicação viral
WO2006016930A2 (fr) 2004-05-14 2006-02-16 Intermune, Inc. Procédés de traitement de l’infection vhc
JP5156374B2 (ja) 2004-05-25 2013-03-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 非環式ｈｃｖプロテアーゼインヒビターの調製方法
CA2556669C (fr) 2004-06-28 2012-05-01 Boehringer Ingelheim International Gmbh Analogues peptidiques d'inhibiteurs de l'hepatite c
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
AR050174A1 (es) 2004-07-16 2006-10-04 Gilead Sciences Inc Derivados de fosfonatos con actividad antiviral. composiciones farmaceuticas
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
EP1771454B1 (fr) 2004-07-20 2011-06-15 Boehringer Ingelheim International GmbH Analogues peptidiques inhibiteurs de l'hepatite c
US7550559B2 (en) 2004-08-27 2009-06-23 Schering Corporation Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
JP2008513454A (ja) 2004-09-17 2008-05-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状ｈｃｖプロテアーゼインヒビターの調製方法
WO2007001406A2 (fr) 2004-10-05 2007-01-04 Chiron Corporation Composes macrocycliques contenant un aryle
CA2583152A1 (fr) 2004-10-21 2006-04-27 Pfizer Inc. Inhibiteurs de la protease du virus de l'hepatite c et compositions et traitements reposant sur l'emploi desdits inhibiteurs
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101160317B (zh) 2005-03-08 2013-03-27 贝林格尔·英格海姆国际有限公司 制备大环化合物的方法
US7879797B2 (en) 2005-05-02 2011-02-01 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20060276404A1 (en) 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
US20070021351A1 (en) 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
US20070004635A1 (en) 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
US20060287248A1 (en) 2005-06-02 2006-12-21 Schering Corporation Asymmetric dosing methods
NZ563365A (en) 2005-06-02 2011-02-25 Schering Corp Combination of HCV protease inhibitors with a surfactant
US20060281689A1 (en) 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
WO2006130607A2 (fr) 2005-06-02 2006-12-07 Schering Corporation Formulation a liberation controlee
US20060276405A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods for treating hepatitis C
WO2006130554A2 (fr) 2005-06-02 2006-12-07 Schering Corporation Methodes de traitement du virus de l'hepatite c
US20060276406A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US8119602B2 (en) 2005-06-02 2012-02-21 Schering Corporation Administration of HCV protease inhibitors in combination with food to improve bioavailability
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
TW200738742A (en) 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
EP1910378B1 (fr) 2005-07-20 2012-06-20 Boehringer Ingelheim International GmbH Analogues de peptides inhibiteurs de l'hepatite c
JP5249028B2 (ja) 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
TWI375670B (en) 2005-07-29 2012-11-01 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
CN101273042B (zh) 2005-07-29 2013-11-06 泰博特克药品有限公司 丙型肝炎病毒的大环抑制剂
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
CN101273030B (zh) 2005-07-29 2012-07-18 泰博特克药品有限公司 丙型肝炎病毒的大环抑制剂
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
TW200745061A (en) 2005-07-29 2007-12-16 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis C virus
RU2419619C2 (ru) 2005-07-29 2011-05-27 Медивир Аб Макроциклические ингибиторы вируса гепатита с
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
ATE496042T1 (de) 2005-07-29 2011-02-15 Tibotec Pharm Ltd Makrocyclische inhibitoren des hepatitis-c-virus
MX2008001402A (es) 2005-07-29 2008-04-04 Tibotec Pharm Ltd Inhibidores macrociclicos del virus de la hepatitis c.
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
JP2009503084A (ja) 2005-08-01 2009-01-29 フェノミックス コーポレーション Ｃ型肝炎セリンプロテアーゼ阻害剤およびその使用
KR20080036598A (ko) 2005-08-01 2008-04-28 머크 앤드 캄파니 인코포레이티드 Ｈｃｖ ｎｓ３ 프로테아제 억제제로서의 마크로사이클릭펩티드
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
DE602006019323D1 (de) 2005-10-11 2011-02-10 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2007082131A1 (fr) 2006-01-09 2007-07-19 Bristol-Myers Squibb Company Procédé de synthèse d’hétérocycles hydroxy-substitués
WO2007106317A2 (fr) 2006-03-03 2007-09-20 Schering Corporation Associations comprenant un ou des inhibiteur(s) de la protease de l'hcv et un ou des inhibiteur(s)de l'ires de l'hcv, et procedes therapeutiques apparentes
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
US8268776B2 (en) 2006-06-06 2012-09-18 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US20070281884A1 (en) 2006-06-06 2007-12-06 Ying Sun Macrocyclic oximyl hepatitis C protease inhibitors
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
UY30437A1 (es) 2006-06-26 2008-01-31 Enanta Pharm Inc Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
KR20090024834A (ko) 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
WO2008008776A2 (fr) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
EA017448B1 (ru) 2006-07-13 2012-12-28 Ачиллион Фармасьютикалз, Инк. 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации
WO2008019289A2 (fr) 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Inhibiteurs de sérine protéases de l'hépatite c macrocycliques de type tétrazolyle
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
WO2008019303A2 (fr) 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Inhibiteurs de sérine protéases de l'hépatite c macrocycliques de type pyridazinonyle
US20090035267A1 (en) 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
US20090035268A1 (en) 2007-08-01 2009-02-05 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
US7687459B2 (en) * 2006-08-11 2010-03-30 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis C virus protease inhibitors
US7582605B2 (en) 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
US20080038225A1 (en) 2006-08-11 2008-02-14 Ying Sun Triazolyl acyclic hepatitis c serine protease inhibitors
WO2008022006A2 (fr) 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Inhibiteurs de protéase du virus de l'hépatite c arylalcoxyle
WO2008021960A2 (fr) 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Inhibiteurs triazolyle macrocycliques de la sérine protéase de l'hépatite c
US7605126B2 (en) 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
WO2008051514A2 (fr) 2006-10-24 2008-05-02 Merck & Co., Inc. Inhibiteurs de la protéase ns3 du hcv
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
AU2007309546A1 (en) 2006-10-24 2008-05-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HCV NS3 protease inhibitors
CN101568346B (zh) 2006-10-27 2015-11-25 默沙东公司 Hcv ns3蛋白酶抑制剂
CA2667031C (fr) 2006-10-27 2013-01-22 Merck & Co., Inc. Inhibiteurs de protease ns3 du vhc
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US20080107625A1 (en) 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US20080107623A1 (en) 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US20080108632A1 (en) 2006-11-02 2008-05-08 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US7772180B2 (en) * 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008070358A2 (fr) 2006-11-16 2008-06-12 Phenomix Corporation Inhibiteurs de la sérine protéase de l'hépatite c et utilisations de ceux-ci
WO2008059046A1 (fr) 2006-11-17 2008-05-22 Tibotec Pharmaceuticals Ltd. Inhibiteurs macrocycliques du virus de l'hépatite c
CN105037347B (zh) 2007-02-01 2018-06-01 泰博特克药品有限公司 Hcv巨环抑制剂的多晶形
PT2121674E (pt) 2007-02-01 2010-09-03 Tibotec Pharm Ltd Processos e intermediários para a preparação de um inibidor macrocíclico da protease do hcv
WO2008095058A1 (fr) 2007-02-01 2008-08-07 Taigen Biotechnology Co. Ltd. Inhibiteurs de la protéase du virus de l'hépatite c
EP2118091B1 (fr) 2007-02-08 2015-04-15 Janssen Sciences Ireland UC Inhibiteurs macrocycliques du virus de l'hépatite c (vhc) substitués par pyrimidine
WO2008096001A1 (fr) 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Phénylcarbamates macrocycliques inhibant le virus de l'hépatite c (vhc)
WO2008096002A1 (fr) 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Phosphonates et amidophosphates macrocycliques inhibiteurs du vhc
WO2008098368A1 (fr) 2007-02-16 2008-08-21 Boehringer Ingelheim International Gmbh Inhibiteurs de la ns3 protéase de l'hépatite c
AU2008217187A1 (en) 2007-02-20 2008-08-28 Novartis Ag Macrocyclic compounds as HCV NS3 protease inhibitors
EP2495249A1 (fr) 2007-02-26 2012-09-05 Achillion Pharmaceuticals, Inc. Peptides à amine tertiaire substituée utiles en tant qu'inhibiteurs de la réplication du VHC
AU2008240834B2 (en) 2007-04-24 2012-08-23 F. Hoffmann-La Roche Ag Process for HCV protease inhibitor intermediate
WO2008134395A1 (fr) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Inhibiteurs macrocycliques azapeptidiques des protéases à sérine du virus de l'hépatite c
WO2008134397A1 (fr) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Inhibiteurs à base d'aza-tripeptide de la sérine protéase de l'hépatite c
US20080279821A1 (en) 2007-04-26 2008-11-13 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors
US20080292587A1 (en) 2007-04-26 2008-11-27 Ying Sun Oximyl dipeptide hepatitis c protease inhibitors
EP2177523A1 (fr) 2007-05-03 2010-04-21 Intermune, Inc. Nouveaux inhibiteurs macrocycliques de réplication du virus de l'hépatite C
JP2010526834A (ja) 2007-05-10 2010-08-05 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規ペプチド阻害剤
US8513186B2 (en) 2007-06-29 2013-08-20 Gilead Sciences, Inc. Antiviral compounds
EP2162431B1 (fr) * 2007-06-29 2017-06-07 Gilead Sciences, Inc. Composés antiviraux
WO2009010804A1 (fr) 2007-07-19 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Composes macrocycliques servant d'agents antiviraux
WO2009014730A1 (fr) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de la sérine protéase
US8202996B2 (en) * 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
EP2250174B1 (fr) * 2008-02-04 2013-08-28 IDENIX Pharmaceuticals, Inc. Inhibiteurs de sérine protéase macrocycliques
US8163921B2 (en) * 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PL2310095T3 (pl) * 2008-07-22 2013-03-29 Msd Italia Srl Makrocykliczne związki chinoksaliny jako inhibitory proteazy NS3 HCV
US8207341B2 (en) * 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines

Also Published As

Publication number Publication date
US8889871B2 (en) 2014-11-18
EP1505963A4 (fr) 2008-12-24
RU2298001C2 (ru) 2007-04-27
EP1505963A1 (fr) 2005-02-16
US8507722B2 (en) 2013-08-13
US8299094B2 (en) 2012-10-30
PE20040517A1 (es) 2004-08-25
US6995174B2 (en) 2006-02-07
TW200403993A (en) 2004-03-16
EP1505963B1 (fr) 2011-04-20
AR090649A2 (es) 2014-11-26
ATE506104T1 (de) 2011-05-15
US20120330019A1 (en) 2012-12-27
RS52407B (en) 2013-02-28
AU2003241510A1 (en) 2003-12-12
NO332427B1 (no) 2012-09-17
KR20100093140A (ko) 2010-08-24
EP2340830A3 (fr) 2011-12-28
DE60336807D1 (en) 2011-06-01
RU2315039C1 (ru) 2008-01-20
IL164987A (en) 2011-06-30
SI1505963T1 (sl) 2011-10-28
CN101024671A (zh) 2007-08-29
US7915291B2 (en) 2011-03-29
RU2004137480A (ru) 2005-08-10
RS100504A (en) 2007-02-05
RU2317303C1 (ru) 2008-02-20
US20110311482A1 (en) 2011-12-22
RU2315039C9 (ru) 2014-02-10
PL373411A1 (en) 2005-08-22
UA80973C2 (uk) 2007-11-26
US20040106559A1 (en) 2004-06-03
EP1505963B9 (fr) 2011-09-21
KR101005958B1 (ko) 2011-01-05
AU2003241510B2 (en) 2006-11-02
CN101024671B (zh) 2010-08-18
TWI306452B (en) 2009-02-21
NZ536539A (en) 2007-02-23
GEP20063938B (en) 2006-10-10
US20060172950A1 (en) 2006-08-03
CA2486308A1 (fr) 2003-12-04
US8710229B2 (en) 2014-04-29
NO20044807L (no) 2004-12-16
DK1505963T3 (da) 2011-08-08
ES2363131T3 (es) 2011-07-21
JP4312710B2 (ja) 2009-08-12
AR087051A2 (es) 2014-02-12
MXPA04011440A (es) 2005-02-14
CA2486308C (fr) 2012-04-10
AR040080A1 (es) 2005-03-16
US9227940B2 (en) 2016-01-05
KR20040111656A (ko) 2004-12-31
US20150005342A1 (en) 2015-01-01
BR0311132A (pt) 2005-03-08
CN1668297A (zh) 2005-09-14
PL226561B1 (pl) 2017-08-31
US20140163231A1 (en) 2014-06-12
ZA200409162B (en) 2006-02-22
WO2003099274A1 (fr) 2003-12-04
HRP20041085B1 (hr) 2014-01-31
MY140680A (en) 2010-01-15
CO5640083A2 (es) 2006-05-31
US20160067302A1 (en) 2016-03-10
IS7530A (is) 2004-11-16
US7449479B2 (en) 2008-11-11
EP2340830A2 (fr) 2011-07-06
US20130267713A1 (en) 2013-10-10
CN1299677C (zh) 2007-02-14
CN1974596B (zh) 2010-07-28
US20090274656A1 (en) 2009-11-05
CY1112108T1 (el) 2015-11-04
US9636375B2 (en) 2017-05-02
HRP20041085A2 (en) 2005-08-31
JP2005533028A (ja) 2005-11-04
CN1974596A (zh) 2007-06-06
IL164987A0 (en) 2005-12-18
PT1505963E (pt) 2011-06-28

Similar Documents

Publication Publication Date Title
HK1070287A1 (en) Hepatitis c virus inhibitors
EP1684787A4 (fr) Inhibiteurs du virus de l'hepatite c
EP1684745A4 (fr) Inhibiteurs du virus de l'hepatite c
SI1414797T1 (sl) Inhibitorji polimeraze virusa hepatitisa c, ki imajo heterobicikliäśno struktuo
HK1078870A1 (en) Heterocyclic tripeptides as hepatitis c inhibitors
IL162673A0 (en) Pharmaceutical compositions for hepatitis c viral protease inhibitors
EG25482A (en) Inhibitors
EP1771453A4 (fr) Analogues dipeptidiques d'inhibiteurs de l'hepatite c
AU2003206862A8 (en) Hepatitis b vaccines
EP1532133A4 (fr) Inhibiteurs de nf-:b
PL376967A1 (pl) Szczepionka przeciw HCV
AU2003294757A8 (en) Formulations useful against hepatitis c virus infections
AU2003256404A8 (en) Hepatitis c virus assays
AU2003230790A1 (en) Hepatitis c virus sub-genomic replicons
AU2003266243A8 (en) 1-carbonyl-4-cyano-pyrrolidine-2-carboxylic acid derivatives as hepatitis c virus inhibitors
GB2393570B (en) Magnetrons
AU2003225479A1 (en) Reporter-selectable hepatitis c virus replicon
AU2006233207A1 (en) Hepatitis C virus inhibitors
GB0208777D0 (en) Shellfish trap
EP1607101A4 (fr) Inhibiteur de la degradation de la proteine interagissant avec la proteine x du virus de l'hepatite b
AU2003263028A1 (en) Mouse hepatitis virus detection
GB0313251D0 (en) Viral inhibitors
SI1654261T1 (sl) Inhibitorske spojine hepatitisa C
GB0229200D0 (en) Hepatitis B vaccines
AU2002351795A1 (en) Hepatitis x virus antigen

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220520